OraSure (OSUR) announced it signed a definitive agreement to acquire BioMedomics. The company said the transaction expands its diagnostic portfolio by adding SickleSCAN, a rapid, point-of-need test for sickle cell disease that is currently sold outside the U.S. OraSure stated it believes it can significantly expand the reach of SickleSCAN by leveraging its international sales channels and existing relationships with national health programs.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OSUR: